

Listing of claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:

- ~~(a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 1001 in SEQ ID NO:40;~~
- ~~(b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 1001 in SEQ ID NO:40;~~
- ~~(c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 42 to about 1001 in SEQ ID NO:40;~~
- (a) ~~(d)~~ a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507;
- (b) ~~(e)~~ a nucleotide sequence encoding the mature TR13 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-507;
- (c) ~~(f)~~ a nucleotide sequence encoding the TR13 extracellular domain encoded by the cDNA clone contained in ATCC Deposit No. PTA-507; and
- (d) ~~(g)~~ a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), or (c), ~~(d), (e), or (f)~~.

2-3. (Canceled)

4. (Previously Presented) The nucleic acid molecule of claim 1, wherein said nucleotide sequence is (a).

5-6. (Canceled)

7. (Previously Presented) The nucleic acid molecule of claim 1, wherein said nucleotide sequence is (b).

8-9. (Canceled)

10. (Previously Presented) The nucleic acid molecule of claim 1, wherein said nucleotide sequence is (c).

11-12. (Canceled)

13. (Previously Presented) The nucleic acid molecule of claim 1, wherein said nucleotide sequence is (d).

14-33. (Canceled)

34. (Original) A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.

35. (Original) A recombinant vector produced by the method of claim 34.

36. (Original) A method of making a recombinant host cell comprising introducing the recombinant vector of claim 35 into a host cell.

37. (Original) A recombinant host cell produced by the method of claim 36.

38. (Original) A recombinant method for producing a TR13 polypeptide, comprising culturing the recombinant host cell of claim 37 under conditions such that said polypeptide is expressed, and recovering said polypeptide.

39-63. (Canceled)

64. (Previously Presented) An isolated nucleic acid molecule comprising a polynucleotide encoding an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 1 to 1001 of SEQ ID NO:40;
- (b) amino acid residues 2 to 1001 of SEQ ID NO:40;

- (c) amino acid residues 42 to 1001 of SEQ ID NO:40;
- (d) amino acid residues 1 to 906 of SEQ ID NO:40;
- (e) amino acid residues 2 to 906 of SEQ ID NO:40; and
- (f) amino acid residues 42 to 906 of SEQ ID NO:40,

65. (Previously Presented) The isolated nucleic acid molecule of claim 64, wherein said amino acid sequence is (a).

66-67. (Canceled)

68. (Previously Presented) The isolated nucleic acid molecule of claim 64, wherein said amino acid sequence is (b).

69-70. (Canceled)

71. (Previously Presented) The isolated nucleic acid molecule of claim 64, wherein said amino acid sequence is (c).

72-76. (Canceled)

77. (Previously Presented) The isolated nucleic acid molecule of claim 64, wherein said amino acid sequence is (d).

78-79. (Canceled)

80. (Previously Presented) The isolated nucleic acid molecule of claim 64, wherein said amino acid sequence is (e).

81-82. (Canceled)

83. (Previously Presented) The isolated nucleic acid molecule of claim 64, wherein said amino acid sequence is (f).

84-88. (Canceled)

89. (Previously presented) An isolated nucleic acid molecule complementary to the isolated nucleic acid molecule of claim 64.

90. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is DNA.

91. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is RNA.

92. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is double-stranded.

93. (Previously presented) The isolated nucleic acid molecule of claim 64, wherein said nucleic acid is single-stranded.

94. (Previously presented) A composition comprising the nucleic acid molecule of claim 64 and a carrier.

95. (Previously presented) The isolated nucleic acid molecule of claim 64 wherein the nucleic acid molecule further comprises a heterologous polynucleotide sequence.

96. (Previously presented) The isolated nucleic acid molecule of claim 95, wherein said heterologous polynucleotide sequence encodes a heterologous polypeptide.

97. (Previously presented) The isolated nucleic acid molecule of claim 96, wherein said heterologous polypeptide is human serum albumin.

98. (Previously presented) The isolated nucleic acid molecule of claim 96, wherein said heterologous polypeptide is a human IgG Fc region.

99. (Previously presented) A recombinant vector comprising the isolated nucleic acid molecule of claim 64.

100. (Previously presented) The recombinant vector of claim 99 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.

101. (Previously presented) A recombinant host cell comprising the isolated nucleic acid molecule of claim 64.

102. (Previously presented) The recombinant host cell of claim 101 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.

103. (Previously Presented) A method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 1 to 1001 of SEQ ID NO:40;
- (b) amino acid residues 2 to 1001 of SEQ ID NO:40;
- (c) amino acid residues 42 to 1001 of SEQ ID NO:40;
- (d) amino acid residues 1 to 906 of SEQ ID NO:40;
- (e) amino acid residues 2 to 906 of SEQ ID NO:40; and
- (f) amino acid residues 42 to 906 of SEQ ID NO:40;

comprising culturing a host cell comprising the nucleic acid molecule of claim 64 under conditions suitable to produce the polypeptide of (a), (b), (c), (d), (e), or (f) and recovering the polypeptide of (a), (b), (c), (d), (e), or (f).

104. (Currently Amended) An isolated nucleic acid molecule comprising a polynucleotide encoding an ~~first~~ amino acid sequence ~~at least 95% identical to a second amino acid sequence~~ selected from the group consisting of:

- ~~(a) the amino acid sequence of the full length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;~~
- (a) ~~(b)~~ the amino acid sequence of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue;

~~(b) the amino acid sequence of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;~~
~~(e) the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;~~
(b) ~~(e)~~ the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue; and
(c) ~~(f)~~ the amino acid sequence of the extracellular domain of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;
wherein said polynucleotide encodes a polypeptide which binds Fas ligand.

105. (Canceled)

106. (Previously presented) The isolated nucleic acid molecule of claim 105, wherein said first amino acid sequence is (a).

107. (Canceled)

108. (Previously presented) The isolated nucleic acid molecule of claim 107, wherein said first amino acid sequence is (b).

109. (Canceled)

110. (Previously presented) The isolated nucleic acid molecule of claim 109, wherein said first amino acid sequence is (c).

111-130. (Canceled)

131. (Previously Presented) A method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;

- (b) the amino acid sequence of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue;
 - (c) the amino acid sequence of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;
 - (d) the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;
 - (e) the amino acid sequence of the extracellular domain of the full-length TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507, minus the N-terminal methionine residue; and
 - (f) the amino acid sequence of the extracellular domain of the mature TR13 polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-507;
- comprising culturing a host cell comprising the nucleic acid molecule of claim 104 under conditions suitable to produce the polypeptide of (a), (b), (c), (d), (e) or (f) and recovering the polypeptide of (a), (b), (c), (d), (e) or (f).

132-159. (Canceled)